Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PARAGON: Phase II study of aromatase inhibitors in recurrent/metastatic gynaecological cancers
2011-000501-52Phase 2Completed
- Sponsor
- NHS Greater Glasgow and Clyde
- Start
- Aug 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anastrozole in ovarian cancer and gynecological cancer, sponsored by NHS Greater Glasgow and Clyde. Primary endpoints: Clinical benefit rate at 3 months and Objective response within 3 months. Started Aug 2011; status: completed.
02
Drugs
anastrozole
03
Conditions
ovarian cancergynecological cancer
Beyond the preview
Go deeper on 2011-000501-52.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000501-52.